Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00703053 · ClinicalTrials.gov registry record · Phase 2
H5N1 Priming and Boosting Strategies
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 505
- Enrollment target
NCT00703053 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 505 participants.
The verdict
NCT00703053, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 505 participants
- Enrollment target
Study Summary
Severe disease in humans due to bird influenza viruses (H5N1) has led to concern that this virus may result in a widespread outbreak of bird flu. The purpose of this study is to evaluate the dose and dosing schedule for 2 different types of H5N1 vaccine. Participants will be randomly assigned to 1 of 9 possible vaccine groups. All participants will receive 2 doses of Clade 1, Clade 2, or combination Clade 1 and 2 on Day 0. All participants will receive a second dose of the same vaccine or a different vaccine type on study day 7, 14, 28 or 180. Study participants will include about 500 healthy adult subjects, ages 18-49 years old, who have no history of prior H5 flu exposure or vaccination. Study procedures may include medical history, physical exam, and blood sampling. Subject participation may last up to 372 days. Several DMID studies have recently evaluated H5N1 vaccines in healthy adults, 04-063, 05-0090, 05-0015, and 05-0043.
Interventions
- BIOLOGICAL A/Vietnam/1203/04
- BIOLOGICAL A/Indonesia/05/05
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 505 participants |
| Start Date | 2008-09 |
| Est. Completion | 2009-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00703053
The ClinicalTrials.gov registry entry for NCT00703053 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 505 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which A/Vietnam/1203/04 is the first listed.
NCT00703053 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00703053 about?
NCT00703053 is a clinical study titled "H5N1 Priming and Boosting Strategies". Severe disease in humans due to bird influenza viruses (H5N1) has led to concern that this virus may result in a widespread outbreak of bird flu. The purpose of this study is to evaluate the dose and dosing schedule for 2 different types of H5N1 vaccine. Participants will be randomly assigned to 1 o...
What is the current status of trial NCT00703053?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 505 participants. The study started on 2008-09. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00703053?
The interventions under investigation include: A/Vietnam/1203/04 (BIOLOGICAL), A/Indonesia/05/05 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00703053?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.